Targeting VPS72 inhibits ACTL6A/MYC axis activity in hepatocellular carcinoma progression. Liu F, Liao Z, Qin L, Zhang Z, et al. Hepatology 2023 Jan 13. doi: 10.1097/HEP.0000000000000268.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu F, Liao Z, Qin L, Zhang Z, et al. Targeting VPS72 inhibits ACTL6A/MYC axis activity in hepatocellular carcinoma progression. Hepatology 2023 Jan 13. doi: 10.1097/HEP.0000000000000268.
PMID: 36631007